Novel DNA-based T-Cell Activator Promotes Rapid T-Cell Activation and Expansion

Abstract

Supplemental Digital Content is available in the text.

Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells

“…We have previously shown that different activation methods affect the proportions of T cell subtypes. 40 We are currently investigating how cells produced in the Prodigy system may differ from CAR T cells produced in bag culture, which could provide insights into whether certain manufacturing platforms are predisposed to a greater sensitivity to cryopreservation. Preliminary results show that cells produced in the Prodigy have a more naive memory cell phenotype, 41 which may be more sensitive to cryopreservation compared with effector memory cells.…”

Objectives, benefits and challenges of bioreactor systems for the clinical-scale expansion of T lymphocyte cells

“…How REP can be improved and refined is still investigated today, for instance with additional medium complements (IL-7, IL-15, anti-CD28 antibodies) but also pre-stimulation with a mix of peptides focusing on pp65 protein, leading to higher proliferation rates in the same culture vessel (Grau-Vorster et al, 2020) (G-Rex flask, see section 7.2). Recent alternatives also include for instance scaffolds mimicking the physiological signal of T cell activation (Zhang et al, 2020), DNAbased platforms to present anti-CD3 and anti-CD28 antibodies (Keskar et al, 2020) or bispecific antibodies (Guo et al, 2020).…”